Acadia (ACHC) Q3 2025 Earnings Call Transcript

Acadia Healthcare reported Q3 revenue of $851.6 million, up 4.4% year over year, but adjusted EBITDA fell to $173 million from $194.3 million and came in about $5 million below internal expectations. Management cut 2025 guidance for revenue to $3.28 billion-$3.3 billion, adjusted EBITDA to $650 million-$660 million, and EPS to $2.35-$2.45 amid Medicaid volume softness, rate pressure, denials, and higher legal costs. The company is also reducing 2026 CapEx by at least $300 million, closing 5 facilities, and expects better free cash flow generation despite ongoing payer headwinds.

Analysis

The print is less about near-term execution and more about a widening reimbursement tax on ACHC’s growth model. The key second-order issue is that the company is still adding beds into a payer environment where incremental utilization is becoming harder to convert into collectible revenue; that is a dangerous mix because it compresses the payoff on capital already deployed while leaving the balance sheet exposed to slower cash conversion. The market should focus on the fact that management is effectively admitting the marginal dollar of growth in Medicaid-heavy markets is worth less than it looked six months ago.

The CapEx reset is the most important bull case element, but it cuts both ways. Yes, lower spend should improve free cash flow in 2026, but it also signals that some of the prior growth pipeline failed the return test; that usually means the market was over-earning on long-dated expansion assumptions. If the 2026 bed additions ramp cleanly, EBITDA can still inflect because startup losses and closure drag fade faster than volume pressure, yet that path depends on payer friction not worsening further into the first half.

The contrarian point is that sentiment may already be too anchored to the headline guidance cut and not enough to the balance sheet optionality. With leverage still manageable and legal expense likely past peak, the stock could rerate if supplemental Medicaid payments land and the company proves that the new bed cohort monetizes faster than feared. The risk is that denials and length-of-stay scrutiny are not a one-quarter issue but a new operating regime; if that’s true, the current multiple is still too high for a lower-quality growth profile.

Competitive dynamics favor operators with stronger commercial mix, better state reimbursement exposure, or less acute-care dependence. That makes ACHC’s JV-heavy strategy attractive on paper, but only if partner facilities preserve utilization while lowering capital intensity. In the near term, the most important catalyst is February guidance: if management shows 2026 EBITDA up despite lower CapEx, the stock can work; if not, the market will reprice it as a levered healthcare roll-up with diminishing marginal returns.

Key Decisions for Investors

• Short ACHC into the next 4-8 weeks on any post-earnings bounce; thesis is that guidance resets usually get multiple compression before the market believes the new run-rate. Risk/reward improves if shares trade near the pre-call level while reimbursement commentary stays defensive.
• If already short ACHC, buy downside protection with 3-6 month puts instead of outright shorting size; the main upside risk is supplemental Medicaid payments and a faster-than-expected 2026 free-cash-flow story.
• Pair trade: long CHE/THC against short ACHC over the next 1-2 quarters to isolate reimbursement quality and lower Medicaid sensitivity. The trade benefits if the market starts paying up for cleaner payer mix and penalizing volume-dependent behavioral exposure.
• Avoid chasing the selloff until February guidance; the stock can overshoot on fear, but the cleaner entry is after management either confirms that payer friction is structural or demonstrates a 2026 earnings inflection. Use that event as the decision point.
• If you must express a bullish view, use a small call spread into February only if there is evidence supplemental payments are approved; otherwise the risk/reward is skewed against paying for upside before the reimbursement overhang clears.